John Stock to Treatment Outcome
This is a "connection" page, showing publications John Stock has written about Treatment Outcome.
Connection Strength
0.097
-
Qu Y, Wong M, Thiebaud D, Stock JL. The effect of raloxifene therapy on the risk of new clinical vertebral fractures at three and six months: a secondary analysis of the MORE trial. Curr Med Res Opin. 2005 Dec; 21(12):1955-9.
Score: 0.030
-
Adachi JD, Adami S, Kulkarni PM, Wong M, Stock JL. Similar proportions of women lose bone mineral density with raloxifene or alendronate treatment. J Clin Densitom. 2005; 8(3):273-7.
Score: 0.028
-
Marcus R, Wong M, Heath H, Stock JL. Antiresorptive treatment of postmenopausal osteoporosis: comparison of study designs and outcomes in large clinical trials with fracture as an endpoint. Endocr Rev. 2002 Feb; 23(1):16-37.
Score: 0.023
-
Grady D, Cauley JA, Stock JL, Cox DA, Mitlak BH, Song J, Cummings SR. Effect of Raloxifene on all-cause mortality. Am J Med. 2010 May; 123(5):469.e1-7.
Score: 0.010
-
Siris ES, Harris ST, Eastell R, Zanchetta JR, Goemaere S, Diez-Perez A, Stock JL, Song J, Qu Y, Kulkarni PM, Siddhanti SR, Wong M, Cummings SR. Skeletal effects of raloxifene after 8 years: results from the continuing outcomes relevant to Evista (CORE) study. J Bone Miner Res. 2005 Sep; 20(9):1514-24.
Score: 0.007